In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time

Circulation

Volumn 95, Issue 3, 1997, Pages 614-617

  Ammar, Tameshwar ^a   Schudder, Lesley E ^b   Coller, Barry S ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

activated clotting time; c7E3 Fab; platelets

Indexed keywords

DEXTRO PHENYLALANYLPROLYLARGINYL CHLOROMETHYL KETONE; FIBRINOGEN RECEPTOR ANTAGONIST; HIRUDIN;

ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING;

EID: 0031041549     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.3.614     Document Type: Article

References (18)

1. Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost. 1995;74:302-308.
2. Topol EJ. Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa inhibitors. Am Heart J. 1995;130:666-672.
3. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
4. Topol EJ, Califf RM, Weisman HF, Ellis EG, James TE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee K, Willerson JT. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;1:881-886.
5. Hattersley PG. Activated coagulation time of whole blood. JAMA. 1966;196:150-154.
6. Lee R, White P. A clinical study of the coagulation time of blood. Am J Med Sci. 1913;145:495-503.
7. Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ. Effects of platelet glycoprotein IIb/IIIa integrin blockade on the activated clotting time during percutaneous transluminal coronary angioplasty or directional alherectomy. Am J Cardiol. 1995;75:559-562.
8. Coller BS, Peerschke El, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal patients and binds to glycoprotein IIb and/or IIIa. J Clin Invest. 1983;72:325-338.
9. 1 in promoting cellular attachment and spreading on fibronectin. J Cell Biol. 1990;111:2795-2800.
10. Coller BS, Scudder LE, Gold HK, Folts JD, Cavagnaro J, Jordan R, Wagner C, luliucci J, Knight D, Ghrayeb J, Smith C, Weisman HF, Berger H. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci. 1991;614:193-213.
11. Coller BS, Cheresh DA, Asch E, Seligsohn U. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thromasthenia in Israel. Blood. 1991;77:75-83.
12. Moorehead MT, Westengard JC, Bull BS. Platelet involvement in the activated clotting time of heparinized blood. Anesth Analg. 1984;63:394-398.
13. Neumann FJ, Gawaz M, Ott I, May A, Mössmer G, Schömig A. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardial 1996;27:15-21.
14. Bray PF, Becker LC, Goldschmidt-Clermont PJ. Differences in platelet fibrinogen binding relate to recurrent myocardial ischemic events and are dependent upon gender, age, and hormonal status. Blood. 1995;86(suppl 1):1188a. Abstract.
15. Trip MD, Cats VM, van Capelle FJL, Vrecken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 1990;322:1549-1554.
16. Weiss EJ, Bray PF, Taybach M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334:1090-1094.
17. Reverter JC, Béguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis.' J Clin Invest. 1996;98:863-874.
18. Okazaki H, Majesky MW, Harker LA, Schwartz SM. Regulation of platelet-derived growth factor ligand and receptor gene expression by α-thrombin in vascular smooth muscle cells. Circ Res. 1992;71:1285-1293.